Michael joins CIC from The Boston Consulting Group’s (BCG) office in Toronto, Canada where he was a Principal in the Healthcare Practice Area. He brings experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy and M&A. Michael is also a co-founder of Proteorex Therapeutics Inc, a Canadian biotechnology company developing small molecule drugs that target protein-protein interactions in disease.
Prior to BCG, Michael worked in venture capital, where he focused on investing in healthcare and life sci-ence businesses. He earned his DPhil in Zoology having been jointly supervised by the Universities of Cambridge and Oxford.
Victor Christou, Chief Executive Officer of CIC, said, “We are delighted to welcome Mike to the CIC team. His arrival further enhances our healthcare investment team, especially given Mike’s knowledge of and connections with large biopharmaceutical companies. I know his skills will be of great benefit to our healthcare portfolio companies and to CIC.”
Cambridge Innovation Capital plc is pleased to announce the appointment of Dr Michael Anstey as an Investment Director specialising in healthcare investments.
Michael joins CIC from The Boston Consulting Group’s (BCG) office in Toronto, Canada where he was a Principal in the Healthcare Practice Area. He brings experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy and M&A. Michael is also a co-founder of Proteorex Therapeutics Inc, a Canadian biotechnology company developing small molecule drugs that target protein-protein interactions in disease.
Prior to BCG, Michael worked in venture capital, where he focused on investing in healthcare and life sci-ence businesses. He earned his DPhil in Zoology having been jointly supervised by the Universities of Cambridge and Oxford.
Victor Christou, Chief Executive Officer of CIC, said, “We are delighted to welcome Mike to the CIC team. His arrival further enhances our healthcare investment team, especially given Mike’s knowledge of and connections with large biopharmaceutical companies. I know his skills will be of great benefit to our healthcare portfolio companies and to CIC.”
Michael added, “Joining the Cambridge Innovation Capital team represents a hugely exciting opportunity. There is an abundance of impressive innovation in bioscience occurring in the Cambridge Cluster and I am thrilled to be working at the heart of it, helping to identify, nurture and grow these companies."